Novus

NVUS NASDAQ
0.7850
-0.0015
-0.19%
已收盘, 16:00 08/16 EDT
开盘
0.7900
昨收
0.7865
最高
0.8022
最低
0.7500
成交量
1.98万
成交均量(3M)
20.91万
52周最高
5.78
52周最低
0.7101
换手率
0.15%
市值
1,018.53万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Novus NVUS股票价格,Novus股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Novus Therapeutics, Inc., formerly Tokai Pharmaceuticals, Inc., is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities. OP-01 is currently being developed as an improved treatment option for acute otitis externa. OP-02 is a daily nasal spray that is designed to improve and maintain a healthy middle ear. OP-02 is being developed as a potential treatment option for patients with otitis media and Eustachian tube dysfunction. OP-02 is a combination drug product, which comprises two components: surfactant dipalmitoylphosphatidylcholine and a spreading agent cholesteryl palmitate. The product is sprayed through the nostrils toward the opening of the Eustachian tube at the back of the nasal cavity.
展开 >

最近浏览

名称
价格
涨跌幅